Advertisement
Research Article Free access | 10.1172/JCI117153
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510.
Find articles by Baron, J. in: JCI | PubMed | Google Scholar
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510.
Find articles by Reich, E. in: JCI | PubMed | Google Scholar
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510.
Find articles by Visintin, I. in: JCI | PubMed | Google Scholar
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510.
Find articles by Janeway, C. in: JCI | PubMed | Google Scholar
Published April 1, 1994 - More info
An adoptive transfer model of insulin-dependent diabetes mellitus (IDDM) in the nonobese diabetic mouse was used to examine the roles of alpha 4-integrin, vascular cell adhesion molecule 1 (VCAM-1); and intercellular adhesion molecule 1 (ICAM-1) in the pathogenesis of autoimmune diabetes. Antibodies specific for both alpha 4-integrin and one of its ligands, VCAM-1, were able to delay onset of diabetes and decrease the incidence of the disease in adoptive transfer studies. This blocking of disease was accompanied by a marked decrease in lymphocytic infiltration of the islets of Langerhans. Furthermore, these antibodies preferentially block entrance of CD4 T cells into the tissue. Antibodies specific for ICAM-1 had little effect on the onset or incidence of IDDM. Thus, we conclude that an alpha 4-integrin-VCAM-1 interaction is important in T cell entry into the islets of Langerhans and in the pathogenesis of IDDM. In addition, the cascade of events leading to T cell transit across endothelium may be different for CD4 and CD8 cells, and may differ depending on the endothelium involved. Our results support the more general conclusion that an alpha 4-integrin-VCAM-1 interaction may be crucial in allowing activated effector CD4T cells to leave the blood and enter tissue to clear infection.
Images.